
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ilika Plc | LSE:IKA | London | Ordinary Share | GB00B608Z994 | ORD 1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
45.00 | 46.00 | 45.50 | 45.50 | 45.50 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 702k | -7.3M | -0.0460 | -10.00 | 72.9M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 45.50 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
24/11/2023 | 07:00 | UKREG | Ilika plc Trading Update, Notice of Results & Presentations |
20/11/2023 | 17:58 | ALNC | ![]() |
20/11/2023 | 07:00 | UKREG | Ilika plc Key Technology Development Milestone |
09/10/2023 | 13:03 | ALNC | ![]() |
09/10/2023 | 06:00 | UKREG | Ilika plc Award of Scale-up Grant Funding for Goliath |
20/9/2023 | 14:20 | UKREG | Ilika plc Result of AGM & Award of Executive Share Options |
18/8/2023 | 06:00 | UKREG | Ilika plc Posting of Annual Report and Notice of AGM |
04/8/2023 | 08:40 | ALNC | ![]() |
04/8/2023 | 06:00 | UKREG | Ilika plc Signed agreement with Cirtec Medical |
13/7/2023 | 08:52 | ALNC | ![]() |
Ilika (IKA) Share Charts1 Year Ilika Chart |
|
1 Month Ilika Chart |
Intraday Ilika Chart |
Date | Time | Title | Posts |
---|---|---|---|
29/11/2023 | 16:38 | ILIKA - Multiple Material Opportunities! | 5,160 |
12/7/2023 | 19:38 | Ilika - First thread | 636 |
30/3/2022 | 19:47 | Ilika (IKA) One to Watch on Monday | 28 |
04/2/2020 | 14:16 | Ilika | 1 |
03/3/2018 | 19:24 | Ilika plc (AIM: IKA) | 29 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
2023-11-29 16:15:43 | 45.25 | 2,810 | 1,271.53 | O |
2023-11-29 15:11:47 | 46.25 | 10,000 | 4,625.00 | O |
2023-11-29 14:41:24 | 45.20 | 554 | 250.41 | O |
2023-11-29 13:56:56 | 45.20 | 2,000 | 904.00 | O |
2023-11-29 13:17:36 | 45.20 | 714 | 322.73 | O |
Top Posts |
---|
Posted at 29/11/2023 08:20 by Ilika Daily Update Ilika Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker IKA. The last closing price for Ilika was 46p.Ilika currently has 158,474,367 shares in issue. The market capitalisation of Ilika is £72,898,209. Ilika has a price to earnings ratio (PE ratio) of -10.00. This morning IKA shares opened at 45.50p |
Posted at 22/11/2023 14:41 by horneblower Utter nonsense.I am not against Ilika. Having traded IKA over many years, I occasionally comment on certain aspects that interest me. If you don't want to hear other peoples' views, that's your problem, not mine. |
Posted at 21/11/2023 13:45 by ivyhedge Please be aware there are very few free float shares for this company. When you get news the price can quite quickly go up. Dont get caught panic buying on the way up wait and it will drift down again. They are a couple of years at least away from making any money. Unless the government puts any meaningfull money to back them or build a factory it will be a very slow burner.I still hold shares so am still in the game but I made a lot of money when they got hyped a couple of years ago I held around 100,000 having bought at a few pence because i invest in shiny technical things. When the hype started I would sell 5000 at 50p, then watch the price go to 100p, i would sell 5000 at 100p and watch the share go to 150p etc...I thought it was great fun but it shouldnt happen like that again. Be cautious dont get caught up in the hype. They have a product in Goliath that should be good but its a long haul still to selling in quantity to rival Tesla battery sales. Buy a few as a gamble then sit on your hands for a few years. The latest news about energy density comparison to Lithium ion has taken them around 5+ years and they still need to acceptance test this several different ways to prove its good....another year or three...by which time someone in government will decide wether we should build a factory then decide its to costly..... |
Posted at 09/11/2023 16:25 by robertspc1 I pretty much agree with what you say. But and it is a big but, does the share price reflect all the past disappointment rather than the potential especially for Goliath. If their technology gets proven out then a big OEM will come knocking at a much higher price. Equally they could screw thongs up as they so nearly did with Stereax |
Posted at 21/9/2023 07:58 by jimmyann Well said Kenjen1. Rogk who has no shares in the company has no idea (look at his past comments) about Ilika. He is here just to pull down the share price. He supposedly asked a complicated question that didn't get answered.Rogk is just full of garbage. |
Posted at 04/8/2023 10:43 by shstt1 Lol, this twerp has been here yrs trying to damage the share price for IKA and therefore validate his terrible trading decisions here of the past. He used to chop and change gettin it wrong every time and having to delete his prior posts. I know you have lost a lot here Rogk or at least what you consider a lot, and it hurts you so much you are bitter and resent the company making progress as you will never profit from it. You are old and have nothing else to do, a sad life for sure. You have made your decision now to stay away from shares but cannot let it go you sad old git spending almost your entire life on here. Someone else said it - you are a saddoI have made good money trading this, currently long from lower and I have tried giving you advice but you just can’t get it. If the market for these super tiny batteries is as big as IKA reckon, I think at this, cirtec will test the mkt and if they think they can make a mint, will swallow IKA up a few yrs down the line Anyway, it’s not the tiny tech that interests me, there aren’t many companies you can invest in that have a solid state battery. The odds are stacked (no pun intended) but the reward is great. |
Posted at 04/8/2023 06:18 by rogk Cirtec deal ain't that good. I believe first business lesson is never, ever grant exclusivity to just one company. Also no upfront cash element or licence fee as far as I can see. Ilika just saved themselves some cash by out sourcing. Share price will probably get a bounce higher by the headline however. |
Posted at 01/8/2023 13:43 by jimmyann They spent it Rogk playing poker!!This guy is desperate to pull the share price down for his benefit. This is all about Rogk and nothing to do with Ilika. |
Posted at 28/7/2023 06:42 by kenjen1 So where are we at then?Stereax manufacturing agreement with cirtec must be close. The company said on investor day it was a couple of weeks away from concluding. That’s was a couple of weeks ago. Quantum scape gave a good technical update yesterday, we could do with one of those on Goliath. QS progressing well and share price was up 25% at one point yesterday. $4b market cap that lot, if only! Things could be about to get interesting here. Share price looking solid at these levels, ready for next leg up? |
Posted at 20/2/2023 04:29 by malnu hxxps://www.ii.co.ukThe Stereax M300 miniature battery should be launched by the summer after some delays last year. A manufacturing licence deal with Cirtec Medical will enable a significant boost in production for Stereax. Machinery will be transferred to Cirtec Medical’s factory in Massachusetts as part of the tech transfer deal. There are initial orders from 18 medical companies and there is plenty of scope for increasing production as required. This is not an exclusive deal and similar deals can be made around the world. Ilika continues to own the intellectual property and it can put more resources into developing the customer base, as well as further investment in the technology. The larger Goliath battery is on the way to reaching parity with equivalent lithium-ion batteries. It is designed to be cost-effective and recyclable. Ilika has been awarded a UK government grant of £2.8 million for taking a leading role on a 24-month Faraday Battery Challenge in collaboration with BMW and Williams. This will further the development of the Goliath battery for automotive use. Net cash was £17.8 million at the end of October 2022. The cash should last well into 2024, but there will be a requirement for more cash as Ilika approaches breakeven. By that time there sh ould be positive news concerning demand for Stereax batteries from medical device companies. The potential for Stereax more than underpins the share price, leaving no value attributed to Goliath. Take a long-term view of this investment. |
Posted at 14/12/2021 08:52 by tp5588 Posted on another site. Credit to original poster:"Thoughts on Investor Day and Site Visit The company has changed a lot since my last site visit (pre-Covid) and is clearly gearing up for commercialisation of their world beating intellectual property. Overall, I was very impressed with progress. Ilika was founded on the back of ground breaking scientific research headed by Prof. Brian Hayden. He and his team have taken the science forward through advanced engineering (Tool 1 and Tool 2 were made bespoke to Ilika’s designs for example) towards commercial reality. My top take-away was that the Ilika’s management are now also adding focus and resources towards commerciality. Most of the traffic on bulletin boards about Ilika seems to be focussed on Goliath (batteries for EV’s). Whilst there was a very full update on Goliath progress (and a tour of the new Goliath Research and Development laboratories), which is going very well (the analysts at Liberum and Berenberg both agreed that none of the big name Goliath competitors were ahead of Ilika in terms of that technology, although they are vastly higher market valuations), I will concentrate this write up on Stereax as it will be the driver of nearer term sales revenue and seems to be less well understood. Bear in mind Ilika are in many ways creating the market through the imminent availability of Stereax batteries in quantities which will allow incorporation in commercial products. The new(ish) VP of Sales and Marketing, John Tinson was clearly out of the highest of top drawers. It was clear that Ilika are determined to nurture their client base (recall ~27 med tech device makers and 11 Internet of Things sensor makers have already been buying Ilika’s Stereax batteries for evaluation, re-certification and research and development purposes). Through his presentation and in Q&A, it was quite obvious that he understood in great detail Stereax’s market segmentation and the price inelastic nature of demand from Med Tech in particular. Tinson made clear that given the limited ability for Ilika to supply in the short term (FAB1 will be able to produce ~£13 mio worth of batteries per annum) that Ilika will be exploiting their understanding of the market for Ilika’s commercial gain. Ilika also hired another Sales VP (who also had an impressive background and who presented very well, but whose name I can’t recall – this is my lack not his; he was equally impressive as John Tinson). Through these extremely high quality hires, it is apparent that Graeme Purdy and his top management team are focussed on turning their scientific and engineering excellence into profits for the shareholders, whilst retaining a leading position in what will be a very rapidly growing market place for nano-scale batteries. As previously advised by the company (and in line with stock exchange rules) no market sensitive information was given. No doubt some PIs foolishly bought in anticipation of the investor day and are now dumping those (tiny) holdings. Frankly, I am sure that long term shareholders would rather not have such myopic people on the share register (which is now over 15% US based according to Steve Boydell CFO). Having said that, personally I think they will be announcing a full year ahead orderbook not long after product validation (which will happen after process validation, as confirmed by Paul Marron, who was clearly totally on top of the production process at FAB1). They are also currently evaluating the relative merits of increasing capacity at FAB1, bringing in-house the rest of the many processes (thinning and dicing for instance) of Stereax production and FAB2 (for which there is space next door…). Recall that the cost of FAB2 was already raised in the May 2020 fund raise (which I am glad to have taken part in). If there is an area of weakness, it was in my opinion their ham-fisted fund-raise of ~£25 mio for Goliath at a 30% discount to the prevailing market. If they needed the money (which they did; in comparison QuantumScape are making losses greater than the entire market capitalisation of Ilika in less than 3 months, every 3 months ...), they should have raised when the share price was rising above £2.75 less than 6 months earlier. This would have resulted in greater funds at lesser dilution. However, that is now in the past and the money at least has been raised and is being put to extremely efficient use. In summary, we already knew that Brian Hayden and his team were world leaders in terms of the tech (both the chemistry and in overcoming engineering problems to turn the science into commercially viable product). The shift of focus to commerciality was definitely needed, but the quality of their hiring shows just how able to evolve this Management team are. They will need to follow this up with results next financial year in terms of Sales and scale-up plans in order to continue to show their effectiveness. I am delighted with their approach of setting realistic guidance and delivering it (rather than making wild claims to gather attention, and then failing to deliver, which any student of the history of the battery industry will know it is littered with). The future looks extremely bright for long term Ilika shareholders imo." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |